GENSTRUCT EXTENDS COLLABORATION IN CANCER WITH GLAXOSMITHKLINE

Genstruct Inc., a knowledge- driven discovery company using systems biology to increase the effectiveness of drug discovery and development, announced that it will begin the second phase of a multi-phase agreement with GlaxoSmithKline plc to jointly investigate compound mechanisms in oncology and to identify biomarkers for patient stratification and drug response. Under the agreement, GSK has paid an upfront fee pursuant to an agreement signed in 2005 and will continue to fund research projects for the term of the agreement. Additional financial terms were not disclosed. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5748/110/)